Subject
Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology
Reference7 articles.
1. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO;Oppenheimer;Ann Allergy Asthma Immunol,2017
2. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO;Chipps;Ann Allergy Asthma Immunol,2017
3. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma;Oba;J Allergy Clin Immunol,2004
4. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO;Luskin;Ann Allergy Asthma Immunol,2018
5. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial;Morishima;Value Health Reg Issues,2013